Total Clarity Wealth Management Inc. Has $932,000 Stake in Eli Lilly and Company (NYSE:LLY)

Total Clarity Wealth Management Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,030 shares of the company’s stock after acquiring an additional 26 shares during the period. Total Clarity Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $932,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of LLY. Tidemark LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $29,000. Core Wealth Advisors Inc. boosted its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares during the last quarter. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company during the 2nd quarter worth approximately $36,000. Finally, Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $37,000. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 17,229 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $902.38, for a total transaction of $15,547,105.02. Following the completion of the sale, the insider now directly owns 97,556,910 shares in the company, valued at $88,033,404,445.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 451,900 shares of company stock valued at $418,732,178 in the last 90 days. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their target price for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Truist Financial reissued a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Finally, Citigroup initiated coverage on shares of Eli Lilly and Company in a research report on Friday. They set a “buy” rating and a $1,060.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $977.35.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $923.71 on Monday. The company has a market capitalization of $877.92 billion, a PE ratio of 136.04, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $972.53. The company has a 50-day simple moving average of $897.12 and a 200 day simple moving average of $833.89.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, research analysts predict that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were given a $1.30 dividend. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.56%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.